Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

Clinical trial NCT04580420 · RECRUITING

Trial details

NCT number: NCT04580420
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Hyperoxaluria Type 1 End Stage Renal Disease

Start date: 2021-04-15
Primary completion: 2031-12-30
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.